Medivation Reports Third Quarter 2009 Financial Results and Provides Corpor...(8 29273 ...),Health

Date:11/4/2009

8 29,273 ====== ====== ====== ====== MEDIVATION, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share data) (unaudited) September December 30, 31, 2009 2008 ---- ---- ASSETS Current assets: Cash and cash equivalents $56,502 $71,454 Short-term investments 157,955 149,968 Receivable from collaboration partner 4,218 3,522 Prepaid expenses and other current assets 6,011 1,957 ----- ----- Total current assets 224,686 226,901 Property and equipment, net 1,070 768 Restricted cash 843 843 Intellectual property, net 51 54 Other non-current assets 694 706 --- --- Total assets $227,344 $229,272 ======== ======== LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $5,447 $7,166 Accrued expenses 12,998 5,772 Deferred revenue 65,361 64,286 Other current liabilities 121 93 --- --
'/>"/>

SOURCE Medivation, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine technology :

1. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
2. Medivations Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimers Disease Patients, Resulting in Reduced Caregiver Distress
3. Medivations Dimebon(TM) Significantly Improved Daily Function in Alzheimers Disease Patients, Resulting in Reduced Need for Caregiver Assistance
4. Medivations Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimers Disease Patients Over One Year
5. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
6. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
7. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
8. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease
9. Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntingtons Disease
10. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
11. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease